Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6617088 | 1.00 | IDO1 (0.40) | IDO1TDO2IDO2TP53MAPT | |
| SCHEMBL6615554 | 0.88 | TP53 (0.47) | TP53MAPTPOLBKMT2A | |
| SCHEMBL6615553 | 0.88 | TP53 (0.47) | TP53MAPTPOLBKMT2A | |
| SCHEMBL6616092 | 0.83 | TP53 (0.47) | IDO1TDO2IDO2TP53MAPT | |
| SCHEMBL6616086 | 0.83 | TP53 (0.47) | IDO1TDO2IDO2TP53MAPT | |
| SCHEMBL6601044 | 0.81 | — | — | |
| SCHEMBL6601034 | 0.81 | — | — | |
| SCHEMBL6617220 | 0.76 | MEN1 (0.54) | POLBKMT2A | |
| SCHEMBL6617217 | 0.76 | MEN1 (0.54) | POLBKMT2A | |
| SCHEMBL6615618 | 0.74 | IDO1 (0.46) | IDO1TDO2IDO2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6136812-A | Methods of administering AMPA receptor antagonists to treat dyskinesias associated with dopamine agonist therapy | PFIZER INC (US) | 2000-10-24 | — | — | US | claimed |
| EP-0900568-A2 | AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy | Pfizer Products Inc. (US) | 1999-03-10 | — | — | EP | claimed |
| US-20200397751-A1 | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia | VANDERKLISH PETER (US) | 2020-12-24 | — | — | US | disclosed |
| WO-2019113110-A2 | MODULATION OF AMPA/KAINATE RECEPTORS FOR THE TREATMENT OF HYPOGLYCEMIA | VANDERKLISH PETER (US) | 2019-06-13 | — | — | WO | disclosed |
| EP-0964860-B1 | ATROPISOMERS OF 3-HETEROARYL-4(3H)-QUINAZOLINONES FOR THE TREATMENT OF NEURODEGENERATIVE AND CNS-TRAUMA RELATED CONDITIONS | PFIZER PROD INC (US) | 2004-04-21 | — | — | EP | disclosed |
| US-6380204-B1 | ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID RECEPTOR ANTAGONIST ACTIVITY | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| US-6136812-A | Methods of administering AMPA receptor antagonists to treat dyskinesias associated with dopamine agonist therapy | PFIZER INC (US) | 2000-10-24 | — | — | US | disclosed |
| EP-0964860-A1 | ATROPISOMERS OF 3-HETEROARYL-4(3H)-QUINAZOLINONES FOR THE TREATMENT OF NEURODEGENERATIVE AND CNS-TRAUMA RELATED CONDITIONS | Pfizer Products Inc. (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0900568-A2 | AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy | Pfizer Products Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1998038187-A1 | ATROPISOMERS OF 3-HETEROARYL-4(3H)-QUINAZOLINONES FOR THE TREATMENT OF NEURODEGENERATIVE AND CNS-TRAUMA RELATED CONDITIONS | PFIZER PRODUCTS INC. (US) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397751-A1 | Modulation of AMPA/kainate Receptors for the Treatment of Hypoglycemia | GPR119, GRIK1, GRIK3 | IDO1 1478/4885TDO2 3862/4885IDO2 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.